Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
PILRA Biologics Sequence Review Report 2026: Paired immunoglobulin-like type 2 receptor alpha Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of PILRA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTCRA Biologics Sequence Review Report 2026: Pre T-cell antigen receptor alpha Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of PTCRA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PILRB Biologics Sequence Review Report 2026: Paired immunoglobulin-like type 2 receptor beta Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of PILRB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NCR3LG1 Biologics Sequence Review Report 2026: Natural cytotoxicity triggering receptor 3 ligand 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of NCR3LG1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NGFR Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 16 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of NGFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MS4A2 Biologics Sequence Review Report 2026: High affinity immunoglobulin epsilon receptor subunit beta Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of MS4A2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
OGFRL1 Biologics Sequence Review Report 2026: Opioid growth factor receptor-like protein 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of OGFRL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LTBR Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LTBR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LAIR2 Biologics Sequence Review Report 2026: Leukocyte-associated immunoglobulin-like receptor 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LAIR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LINGO3 Biologics Sequence Review Report 2026: Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LINGO3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LINGO4 Biologics Sequence Review Report 2026: Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 4 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LINGO4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR3DX1 Biologics Sequence Review Report 2026: Putative killer cell immunoglobulin-like receptor-like protein KIR3DX1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR3DX1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.